Haematologica · 2009 · 62 citations · 18 references
MedicineOncologyPharmacotherapyChemotherapyMedical OncologyOncology PharmacotherapyCancer ImmunotherapyChemotherapy In Hematologic MalignanciesCombination ChemotherapyHematologic Malignancy TherapyBortezomib TherapyBortezomib-based RegimensBortezomib-based TherapyLymphoma ChemotherapyLymphoma Treatment ResponsePartial Response AssessmentPhase Ii InvestigationStudy Phase
We have performed a phase II study to evaluate bortezomib in patients with MALT-lymphoma. Sixteen patients entered the trial, 4 had gastric MALT-lymphoma, 7 of the ocular adnexa, one of the colon, and 2 of the parotid, and one patient each the lung and the breast. Bortezomib was given at 1.5 mg/m(2) days 1, 4, 8 and 11; repeated every 21 days. The overall response rate was 80% (13/16); 7 patients achieved complete remission (43%), 6 partial response (37%) and 3 stable disease. After a median follow-up of 23 months (range; 8-26), all patients are alive and 4 have relapsed. Fifteen patients required dose reductions due to either neuropathy (7 patients) or diarrhea (8 patients). Bortezomib appears to be active in patients with MALT-lymphoma. However, an unexpectedly high rate of toxicities was seen, warranting assessment of combination schedules with bortezomib at a lower dose than given in our study.
18
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
Teru Hideshima, Constantine S. Mitsiades, Masaharu Akiyama et al. · Blood · 2003 · 569 citations · Full text
Medicine, Oncology, Pharmacology +13